scholarly journals FRI0205 ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Author(s):  
Ioannis Parodis ◽  
Sofia Soukka ◽  
Alvaro Gomez ◽  
Yvonne Enman ◽  
Petter Johansson ◽  
...  
2020 ◽  
Vol 9 (6) ◽  
pp. 1813
Author(s):  
Alvaro Gomez ◽  
Sofia Soukka ◽  
Petter Johansson ◽  
Emil Åkerström ◽  
Sharzad Emamikia ◽  
...  

Impaired health-related quality of life (HRQoL) is a major problem in patients with systemic lupus erythematosus (SLE). Antimalarial agents (AMA) are the cornerstone of SLE therapy, but data on their impact on HRQoL are scarce. We investigated this impact using baseline data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (n = 1684). HRQoL was self-reported using the Medical Outcomes Study short-form 36 (SF-36), functional assessment of chronic illness therapy (FACIT)-Fatigue and 3-level EuroQoL 5-Dimension (EQ-5D) questionnaires. Patients on AMA (n = 1098/1684) performed better with regard to SF-36 physical component summary, physical functioning, role physical, bodily pain, FACIT-Fatigue, EQ-5D utility index and EQ-5D visual analogue scale scores. The difference in SF-36 physical functioning (mean ± standard deviation (SD): 61.1 ± 24.9 versus 55.0 ± 26.5; p < 0.001) exceeded the minimal clinically important difference (≥5.0). This association remained significant after adjustment for potential confounding factors in linear regression models (standardised coefficient, β = 0.07; p = 0.002). Greater proportions of AMA users than non-users reported no problems in the mobility, self-care, usual activities and anxiety/depression EQ-5D dimensions. AMA use was particularly associated with favourable HRQoL in physical aspects among patients with active mucocutaneous and musculoskeletal disease, and mental aspects among patients with active renal SLE. These results provide support in motivating adherence to AMA therapy. Exploration of causality in the relationship between AMA use and favourable HRQoL in SLE has merit.


2019 ◽  
Author(s):  
Ioannis Parodis ◽  
Sofia Soukka ◽  
Alvaro Gomez ◽  
Petter Johansson ◽  
Sharzad Emamikia ◽  
...  

2019 ◽  
Vol 18 (10) ◽  
pp. 102372 ◽  
Author(s):  
Borja Hernández-Breijo ◽  
Alvaro Gomez ◽  
Sofia Soukka ◽  
Petter Johansson ◽  
Ioannis Parodis

2010 ◽  
Vol 38 (2) ◽  
pp. 271-274 ◽  
Author(s):  
SASHA BERNATSKY ◽  
CHRISTINE PESCHKEN ◽  
PAUL R. FORTIN ◽  
CHRISTI A. PINEAU ◽  
MURRAY B. UROWITZ ◽  
...  

Objective.To evaluate factors affecting therapeutic approaches used in clinical practice for the management of systemic lupus erythematosus (SLE), in a multicenter cohort.Methods.We combined data from 10 clinical adult SLE cohort registries in Canada. We used multivariate generalized estimating equation methods to model dichotomized outcomes, running separate regressions where the outcome was current exposure of the patient to specific medications. Potential predictors of medication use included demographic (baseline age, sex, residence, race/ethnicity) and clinical factors (disease duration, time-dependent damage index scores, and adjusted mean SLE Disease Activity Index-2K scores). The models also adjusted for clustering by center.Results.Higher disease activity and damage scores were each independent predictors of exposure to nonsteroid immunosuppressive agents, and for exposure to prednisone. This was not definitely demonstrated for antimalarial agents. Older age at diagnosis was independently and inversely associated with exposure to any of the agents studied (immunosuppressive agents, prednisone, and antimalarial agents). An additional independent predictor of prednisone exposure was black race/ethnicity (adjusted RR 1.46, 95% CI 1.18, 1.81). For immunosuppressive exposure, an additional independent predictor was race/ethnicity, with greater exposure among Asians (RR 1.39, 95% CI 1.02, 1.89) and persons identifying themselves as First Nations/Inuit (2.09, 95% CI 1.43, 3.04) than among whites. All of these findings were reproduced when adjustment for disease activity was limited to renal involvement.Conclusion.Ours is the first portrayal of determinants of clinical practice patterns in SLE, and offers interesting real-world insights. Further work, including efforts to determine how differing clinical approaches may influence outcome, is in progress.


2021 ◽  
Vol 64 (2) ◽  
pp. 109-115
Author(s):  
Sung-Hoon Park

Systemic lupus erythematosus is a typical autoimmune disease with a complex etiology, including the interaction of genetic/epigenetic factors and environmental and hormonal factors with innate immune cells or B/T lymphocytes. Studies on possible therapeutic targets have been conducted in recent decades, motivated by developments in immunology and molecular engineering. The current treatment guidelines recommend conventional immunomodulation with glucocorticoid and antimalarial agents depending on disease severity. However, targeted therapy based on the diverse disease pathophysiology is still not established and widely applied. Furthermore, although rituximab, belimumab, and other conventional immunomodulators have been approved by the Food and Drug Administration and are widely used, several clinical trials testing other biological products have failed to show satisfactory results. This review introduces novel biological agents that can potentially improve therapeutic performance in patients with systemic lupus erythematosus. These agents include humanized anti-CD20, anti-CD22, and anti-CD40L antibody; interferon α inhibitor; rigerimod; Bruton’s tyrosine kinase; and immunocomplex blockers.


2020 ◽  
Vol 2 (1) ◽  
pp. 165-170
Author(s):  
Fadillah Maulidia

Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease that attacks various organs. Antimalarial agents are part of an immunomodulatory regimen that is used to cure patients with SLE. Not all antimalarial agents can be used in the treatment of lupus; This review lends to the study of the use of chloroquine. Overall, antimalarial drugs have many beneficial effects in patients with SLE, and have a good safety profile. According to the American College of Rheumatology (ACR) the diagnosis of SLE was originally established to be found at least 2 or more than 11 criteria. The classification degrees are divided into mild, moderate and severe SLE. The recommended use of base chloroquine 3.5-4.0 mg / kg BW / day (150-300 mg / day) is only used in mild SLE.


Sign in / Sign up

Export Citation Format

Share Document